CLPT ClearPoint Neuro
- 12.060
- -0.080-0.66%
ClearPoint Neuro News
Market Participants Recognise ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Revenues Pushing Shares 28% Higher
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
ClearPoint Neuro Shares Are Trading Higher After the Company Announced the Early Repayment of a $10 Million Convertible Note to PTC Therapeutics. Additionally, Lake Street Raised Its Price Target on the Stock From $11 to $15.
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Raises Target Price to $15
Lake Street analyst Frank Takkinen maintains $ClearPoint Neuro(CLPT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 46.7% and a total average return of 1.1% over
Lake Street Sticks to Their Buy Rating for ClearPoint Neuro (CLPT)
Lake Street Reaffirms Their Buy Rating on ClearPoint Neuro (CLPT)
Lake Street Maintains Buy on ClearPoint Neuro, Raises Price Target to $15
ClearPoint Neuro Analyst Ratings
ClearPoint Neuro Preempts Convertible Note Obligations
ClearPoint Neuro Announces Full Early Repayment Of $10M Convertible Note To PTC Therapeutics Ahead Of January 2025 Maturity
ClearPoint Neuro Announces Early Repayment of $10 Million Note
Express News | Clearpoint Neuro Announces Early Repayment of $10 Million Note
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Earnings Call: ClearPoint Neuro Sees Record Revenue of $7.9 Million
Earnings Call Summary | ClearPoint Neuro(CLPT.US) Q2 2024 Earnings Conference
B. Riley Adjusts Price Target on ClearPoint Neuro to $10.50 From $10, Maintains Buy Rating
Express News | Clearpoint Neuro Inc : Stifel Raises Target Price to $10 From $9
ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript
ClearPoint Neuro | 10-Q: Q2 2024 Earnings Report
ClearPoint Neuro Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results.
Analysis
Price Target
No Data
No Data
